Результаты поиска

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.

Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach to managing NETs. Recent advances in the management of NETs aim to enhance the effectiveness of targeted treatment with either modifications of known substances or the development of new substances with better targeting features. There have been several attempts to increase the detectability of NET

Совпадение в полном тексте источника
… Alpha Radiopeptide Therapy Alpha particles cause more double strand DNA breaks than beta particles because of the formers’ much higher linear energy transfer. Furthermore, the short range of alpha particles preserves the surrounding non-tumor tissue. … Lead-212 is a beta particle and the parent nuclide of the alpha particle Bismuth-212; in this way it acts as an “in vivo generator” for alpha particles. The study objectives are the assessment of the safety and efficacy of [ 212 Pb]Pb-DOTAMTATE. …

Ocular complications with the use of radium-223: a case series.

BackgroundRadium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life. It is well tolerated, with hematologic toxicity as the main adverse event. Thus far, no ocular complication has been reported in the literature after initial administration of radium-223 with a single case reported of ocular complications after a patient's second course of radium-223.Case presentationsWe present three cases of ocular complications afte

Совпадение в полном тексте источника
… It has a half-life of 11.4 days; with each decay, it emits four alpha-particles with high linear energy transfer of 27.4 MeV [ 8 ]. … High energy alpha particles emitted induce DNA double-strand breaks, leading to cell death in tumor cells and nearby osteoblasts and osteoclasts. …

The research progress on radionuclides in osteoporosis diagnosis and drug efficacy monitoring.

Osteoporosis is a common metabolic bone disease that seriously affects the quality of life and health of patients. Traditional diagnostic methods, such as dual energy X-ray absorptiometry (DXA), have limitations in early detection and dynamic monitoring, making it difficult to meet clinical needs. This paper focuses on the potential of radionuclide imaging techniques, such as Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), in the early diagnosis of osteoporosis. The paper further elaborates on the importance of radionuclides in evaluating the therapeu

Совпадение в полном тексте источника
… These atomic nuclei emit radiation or particles during the decay process, such as alpha particles, beta particles, gamma rays, or X-rays, which release energy to transform into a more stable state. … In the treatment of certain diseases, especially tumors, the most commonly used radioactive particles include beta particles and alpha particles. Beta particles are electrons or positrons, while alpha particles are helium nuclei composed of two protons and two neutrons. …

Radionuclide-labelled nanoparticles for cancer combination therapy: a review.

Radionuclide therapy (RT) is widely used to advanced local cancers. However, its therapeutic efficacy is limited to the radiation resistance of cancer cells. Combination therapy aims to circumvent tumor resistance, and the combination of RT with photothermal therapy (PTT), photodynamic therapy (PDT), chemotherapy (CMT), and immunotherapy has shown promising treatment outcomes. Nanotechnology holds promise in advancing combination therapy by integrating multiple therapies on a nanostructure platform. This is due to the increased surface area, passive/active targeting capabilities, high payload

Протеомический анализ показывает, что потенциальные молекулы могут выступать посредником в кортикальной патологии и выявлять возможные биомаркеры в животной модели множественного склероза.

ВВЕДЕНИЕ: Множественный склероз (MS) представляет собой сложное нейродегенеративное заболевание, характеризующееся повторяющимися вспышками, обезвоживанием, повреждением аксона и последующей потерей функции. MS представляет широкий спектр клинических курсов, прогрессивные формы которых приводят к необратимой неврологической инвалидности. Кортикальные демиелионирующие повреждения имеют ключевое значение для патологии этих прогрессивных форм, и в последние десятилетия они приобретают решающее значение в силу их тесной связи с физической инвалидностью и когнитивным упадком. Несмотря на это, механ

Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice.

BackgroundGlioblastoma (GB), the most aggressive brain cancer, remains a critical clinical challenge due to its resistance to conventional treatments. Here, we introduce a locoregional targeted-α-therapy (TAT) with the rat monoclonal antibody 9E7.4 targeting murine syndecan-1 (SDC1) coupled to the α-emitter radionuclide astatine-211 (211At-9E7.4).MethodsWe orthotopically transplanted 50,000 GL261 cells of murine GB into the right striatum of syngeneic female C57BL/6JRj mice using stereotaxis. After MRI validation of tumour presence at day 11, TAT was injected at the same coordinates. Biodistri

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.

Radiopharmaceuticals (RPhs) represent a breakthrough in nuclear medicine due to their ability to provide precise diagnosis and targeted therapy for cancer by incorporating radioactive isotopes into carrier molecules. This review systematically discusses the recent advances in the development of RPhs, focusing on state-of-the-art probe design strategies and click chemistry applications that accelerate RPh syntheses and improve targeting efficiency. The manuscript synthesizes literature from multiple databases spanning January 2014 to April 2025, encompassing diagnostic modalities including posi

Совпадение в полном тексте источника
… Mechanisms of Action for Alpha and Beta Emitters Mechanisms of Action of Alpha Emitters Alpha particles cause their effects via distinct physical and molecular mechanisms. … This concentrated energy deposition produces ionization tracks, resulting in significant molecular destruction. [ 122 ] At the molecular level, alpha particles cause damage via both direct and indirect pathways. …

The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis.

The aim of this study was to assess the effect of naringenin on osteoclastogenesis and titanium particle-induced osteolysis. Osteolysis from wear-induced particles and aseptic loosening are the most frequent late complications of total joint arthroplasty leading to revision of the prosthesis. Osteolysis during aseptic loosening is most likely due to increased bone resorption by osteoclasts. Through in vitro studies, we demonstrated that naringenin, a naturally occurring flavanone in grapefruit and tomatoes, exerts potent inhibitory effects on the ligand of the receptor activator of nuclear fac

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.

Radiopharmaceutical therapy, which can detect and treat tumours simultaneously, was introduced more than 80 years ago, and it has changed medical strategies with respect to cancer. Many radioactive radionuclides have been developed, and functional, molecularly modified radiolabelled peptides have been used to produce biomolecules and therapeutics that are vastly utilised in the field of radio medicine. Since the 1990s, they have smoothly transitioned into clinical application, and as of today, a wide variety of radiolabelled radionuclide derivatives have been examined and evaluated in various

Nanotherapeutics in the EU: an overview on current state and future directions.

The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug's therapeutic index, and reduce a drug's immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most suc

Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review.

Advanced prostate cancer (PCa) is still an incurable disease. Still, the field of PSMA-targeted radioligand therapy is developing rapidly and is playing an increasingly important role in the treatment of advanced Pca in the future. As an α -particle emitter, Ac-225 shows a potent killing ability for tumor cells due to its short range and high energy deposition in the tumor micrometastasis focus. However, the secondary myelofibrosis (SMF) associated with Ac-225-PSMA-617 treatment is a significant concern. We present a case of metastatic castration-resistant prostate cancer (mCRPC) who developed

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.

Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibi

Совпадение в полном тексте источника
… An alpha particle, which is ejected from a heavy nucleus during alpha decay, consists of two neutrons and two protons. A beta particle is an electron released from a nucleus containing excess neutrons during beta decay, in which one neutron is converted to a proton, an electron, and a neutrino. … Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation. Oncology. 2012;26(4):330–337, 341. 59. Nilsson S, Franzén L, Parker C, et al. …

Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.

As new molecular tracers are identified to target specific receptors, tissue, and tumor types, opportunities arise for the development of both diagnostic tracers and their therapeutic counterparts, termed "theranostics." While diagnostic tracers utilize positron emitters or gamma-emitting radionuclides, their theranostic counterparts are typically bound to beta and alpha emitters, which can deliver specific and localized radiation to targets with minimal collateral damage to uninvolved surrounding structures. This is an exciting time in molecular imaging and therapy and a step towards personal

Effect of PLA2G6 and SMPD1 Variants on the Lipid Metabolism in the Cerebrospinal Fluid of Patients with Parkinson's Disease: A Non-targeted Lipidomics Study.

IntroductionSleep patterns are more frequently interrupted in patients with Parkinson's disease (PD), and it is still unclear whether genetic factors are involved in PD-related sleep disorders. In this study, we hypothesize that PD-associated genetic risk affects lipid metabolism, which in turn contributes to different types of sleep disorders.MethodsWe used a non-targeted lipidomics to explore the lipid composition of cerebrospinal fluid (CSF) exosomes derived from patients with PD carrying phospholipase A2 Group VI (PLA2G6) and sphingomyelin phosphodiesterase 1 (SMPD1) mutations.ResultsPLA2G

Theranostics - a sure cure for cancer after 100 years?

Cancer has remained a formidable challenge in medicine and has claimed an enormous number of lives worldwide. Theranostics, combining diagnostic methods with personalized therapeutic approaches, shows huge potential to advance the battle against cancer. This review aims to provide an overview of theranostics in oncology: exploring its history, current advances, challenges, and prospects. We present the fundamental evolution of theranostics from radiotherapeutics, cellular therapeutics, and nanotherapeutics, showcasing critical milestones in the last decade. From the early concept of targeted d

Совпадение в полном тексте источника
… Alpha particles have a shorter tissue range but a considerably higher linear energy transfer (LET; 50-230 keV), hence, they are more potent to induce cytotoxicity than β¯-particles emitted by lutetium-177. …

Стратегия FACS-Proteomics, направленная на экстраклелектальную эмоциональную характеристику однофенотипов в биологических жидкостях: изучение роли лейкоцитных ЭМ в множественном склерозе.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Изоляция и протеомика внеклеточной везиклетки (ЭМ) от жидкостей организма сопряжены с трудностями из-за их большой неоднородности. Недавно мы продемонстрировали, что срабатывание ячеек (FACS) с флюоресцентной активацией эффективно изолирует весь ЭМ-диапазон непосредственно от нетронутых жидкостей тела, что позволяет провести всеобъемлющий протеомикальный анализ ЭМ. Здесь мы впервые описали однофенотипный ЭВ, сортируя лейкоцитные ЭВ (Leuko EVs) из периферической крови и слез здоровых добровольцев.Используя оптимизированный и запатентованный протокол пятна всего ЭМ-отсека,

Chemotherapy- and irradiation-induced bone loss in adults with solid tumors.

It is estimated that bone loss occurs in 70 % of all patients dying from cancer, causing a significant disease burden in cancer patients. Bone loss is caused by cancer itself and its metastases, but also by cancer therapies. Of the cancer therapy-induced bone loss, hormone therapies are best known for their bone damaging abilities. However, chemo- and radiotherapy may result in bone loss too. In this review, direct and indirect effects of various chemotherapies (such as methotrexate, imatinib, and taxanes) that cause bone loss are discussed. Furthermore, we discuss bone loss caused by radiothe

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.

'See what you treat and treat what you see, at a molecular level', could be the motto of theranostics. The concept implies diagnosis (imaging) and treatment of cells (usually cancer) using the same molecule, thus guaranteeing a targeted cytotoxic approach of the imaged tumor cells while sparing healthy tissues. As the brilliant late Sam Gambhir would say, the imaging agent acts like a 'molecular spy' and reveals where the tumoral cells are located and the extent of disease burden (diagnosis). For treatment, the same 'molecular spy' docks to the same tumor cells, this time delivering cytotoxic

Совпадение в полном тексте источника
… Treatment with alpha particles like Radium-223 ( 223 Ra) has been approved by the US Food and Drug Administration (FDA), others like Actinium-225 ( 225 Ac) are being actively researched in human clinical trials. … Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial Clin Cancer Res 2019 25 3802 10 30733229 10.1158/1078-0432.CCR-18-3964 PMC6606382 104 Maris JM Recent advances in neuroblastoma N Engl J Med 2010 362 2202 11 20558371 10.1056/NEJMra0804577 PMC3306838 105 Whittle …

Women suffering from overactive bladder syndrome exhibit a higher urethral viral abundance compared to healthy controls: a pilot study.

The interactions between the human bacterial microbiome and essential bodily functions are well established for organ systems such as the oral cavity, gut, and female reproductive tract. However, the urinary microbiome, particularly its viral component, remains largely unexplored. Emerging evidence suggests that the urinary microbiome may play a significant role in the development of overactive bladder syndrome (OAB). This study aims to fill this knowledge gap by investigating the potential link between the urethral virome and female overactive bladder syndrome, and by aligning these findings

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation.

Innovative strategies to re-establish the immune-mediated destruction of malignant cells is paramount to the success of anti-cancer therapy. Accumulating evidence suggests that radiotherapy and select chemotherapeutic drugs and small molecule inhibitors induce immunogenic cell stress on tumors that results in improved immune recognition and targeting of the malignant cells. Through immunogenic cell death, which entails the release of antigens and danger signals, and immunogenic modulation, wherein the phenotype of stressed cells is altered to become more susceptible to immune attack, radiother